These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

278 related items for PubMed ID: 17056129

  • 1. Neuroprotective effects of huperzine A: new therapeutic targets for neurodegenerative disease.
    Zhang HY, Tang XC.
    Trends Pharmacol Sci; 2006 Dec; 27(12):619-25. PubMed ID: 17056129
    [Abstract] [Full Text] [Related]

  • 2. Potential therapeutic targets of huperzine A for Alzheimer's disease and vascular dementia.
    Zhang HY, Zheng CY, Yan H, Wang ZF, Tang LL, Gao X, Tang XC.
    Chem Biol Interact; 2008 Sep 25; 175(1-3):396-402. PubMed ID: 18565502
    [Abstract] [Full Text] [Related]

  • 3. Progress in studies of huperzine A, a natural cholinesterase inhibitor from Chinese herbal medicine.
    Wang R, Yan H, Tang XC.
    Acta Pharmacol Sin; 2006 Jan 25; 27(1):1-26. PubMed ID: 16364207
    [Abstract] [Full Text] [Related]

  • 4. Neuroprotective effects of huperzine A. A natural cholinesterase inhibitor for the treatment of Alzheimer's disease.
    Wang R, Tang XC.
    Neurosignals; 2005 Jan 25; 14(1-2):71-82. PubMed ID: 15956816
    [Abstract] [Full Text] [Related]

  • 5. Role of huperzine a in the treatment of Alzheimer's disease.
    Desilets AR, Gickas JJ, Dunican KC.
    Ann Pharmacother; 2009 Mar 25; 43(3):514-8. PubMed ID: 19240260
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Mechanisms behind the neuroprotective actions of cholinesterase inhibitors in Alzheimer disease.
    Nordberg A.
    Alzheimer Dis Assoc Disord; 2006 Mar 25; 20(2 Suppl 1):S12-8. PubMed ID: 16772751
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. From anti-Parkinson's drug rasagiline to novel multitarget iron chelators with acetylcholinesterase and monoamine oxidase inhibitory and neuroprotective properties for Alzheimer's disease.
    Zheng H, Amit T, Bar-Am O, Fridkin M, Youdim MB, Mandel SA.
    J Alzheimers Dis; 2012 Mar 25; 30(1):1-16. PubMed ID: 22387411
    [Abstract] [Full Text] [Related]

  • 14. Huperzine a as potential treatment of Alzheimer's disease: an assessment on chemistry, pharmacology, and clinical studies.
    Ha GT, Wong RK, Zhang Y.
    Chem Biodivers; 2011 Jul 25; 8(7):1189-204. PubMed ID: 21766442
    [Abstract] [Full Text] [Related]

  • 15. Effects of huperzine A on secretion of nerve growth factor in cultured rat cortical astrocytes and neurite outgrowth in rat PC12 cells.
    Tang LL, Wang R, Tang XC.
    Acta Pharmacol Sin; 2005 Jun 25; 26(6):673-8. PubMed ID: 15916732
    [Abstract] [Full Text] [Related]

  • 16. Iron dysregulation in Alzheimer's disease: multimodal brain permeable iron chelating drugs, possessing neuroprotective-neurorescue and amyloid precursor protein-processing regulatory activities as therapeutic agents.
    Mandel S, Amit T, Bar-Am O, Youdim MB.
    Prog Neurobiol; 2007 Aug 25; 82(6):348-60. PubMed ID: 17659826
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 14.